Tumor News and Research

RSS

Boston Scientific signs definitive agreement to acquire CeloNova's interventional radiology business

Boston Scientific has entered into a definitive agreement to acquire the interventional radiology portfolio of CeloNova Biosciences, a San Antonio-based developer of endovascular and interventional cardiology technologies.

10 Nov 2015

New findings reveal association between colorectal cancer and melanoma drug treatment

Veteran cancer reseacher Prof. Emeritus Alexander Levitzki of Hebrew University of Jerusalem says new findings show link between colorectal cancer and melanoma drug treatment knoqwn as "NT157" in two recently published studies in journal, "Ocogene."

10 Nov 2015

Researchers find greater genetic diversity among cancer cells than anticipated

The most rigorous genetic sequencing ever carried out on a single tumor reveals far greater genetic diversity among cancer cells than anticipated. Researchers from the University of Chicago and the Beijing Institute of Genomics estimate that the tumor, about 3.5 centimeters in diameter, contained more than 100 million distinct mutations within the coding regions of its genes—thousands of times more than expected.

10 Nov 2015

New method may extend use of noninvasive prenatal testing to detect chromosomal abnormalities

Researchers at the University of California, San Diego School of Medicine developed a method to expand the types of chromosomal abnormalities that noninvasive prenatal testing (NIPT) can detect. The study, published November 9 by Proceedings of the National Academy of Sciences, uses a semiconductor sequencing platform to identify small chromosomal deletions or duplications, such as occur in Cri du Chat Syndrome and DiGeorge Syndrome, with a simple blood test from the expectant mother.

10 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

NanoString Technologies, Inc.a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of its 3D Biology™ portfolio with the commercial launch of the nCounter® PanCancer Profiles, seven new gene expression panels each designed to interrogate a focused area of cancer biology including immuno-oncology.

9 Nov 2015

No progression in joint damage in 84% of psoriatic arthritis patients

Novartis announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.

9 Nov 2015

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Novartis announced today late-breaking two year results for Cosentyx® (secukinumab) showing up to 80% of patients with ankylosing spondylitis (AS) had no radiographic progression in the spine on x-ray assessment. This is the first time that data on structural spinal progression in AS have been presented for an interleukin-17A (IL-17A) inhibitor.

9 Nov 2015

New tool could help identify patients most likely to benefit from chemoprevention

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

6 Nov 2015

Specific gut bacteria can improve cancer immunotherapy, show studies

By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers at the University of Chicago were able to boost the ability of the animal's immune systems to attack tumor cells. T

6 Nov 2015

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

CytomX Therapeutics, a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies.

6 Nov 2015

Researchers identify new regulatory pathway that may play vital role in basal-like breast cancer

Researchers have identified a new regulatory pathway that may play an important role in basal-like breast cancer (BLBC), a particularly aggressive form of breast cancer often referred to as "triple negative." This pathway may serve as a target for the development of an effective therapeutic.

5 Nov 2015

Man dies after developing tapeworm tumors

A man has died as a result of tapeworm tumors growing inside his body, doctors report.

5 Nov 2015

Differences in vitamin D status may account for disparities in breast cancer survival rates

The American Cancer Society just published a paper reporting that while breast cancer incidence rates for 2008-2012 were similar for black and white women, death rates were 42% higher for black women [DeSantis, 2015]. The factors suggested to explain the disparity in mortality rates included difference in stage at diagnosis, obesity, comorbidities, tumor characteristics, as well as access, adherence, and response to treatments.

5 Nov 2015

Accuray announces installation of CyberKnife M6 and TomoTherapy Systems at FALP Cancer Institute in Chile

Accuray Incorporated announced today that the first CyberKnife M6 and TomoTherapy Systems in Chile are now installed at Fundacion Arturo Lopez Perez (FALP) Cancer Institute in Santiago, Chile. FALP is also the first hospital in Latin America to install both Accuray systems.

5 Nov 2015

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating subcutaneous (SC) delivery of daratumumab with Halozyme's proprietary ENHANZE technology in multiple myeloma.

5 Nov 2015

Liquid biopsy provides physicians with up-to-date information about patient's cancer

A team of researchers, including scientists from the Translational Genomics Research Institute, has reported that analyzing circulating tumor DNA (ctDNA) can track how a patient's cancer evolves and responds to treatment.

5 Nov 2015

Drugs that target malignant cells increase life expectancy in advanced breast cancer patients

Clinical studies show that new drugs that target malignant cells of HER2-positive breast cancer, such as Pertuzumab and Trastuzumab Emtansine (T-DM1), increase life expectancy in patients with advanced breast cancer.

5 Nov 2015

CK5 protein marks ovarian cancer likely to be resistant to cisplatin

A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.

5 Nov 2015

Tumor News and Research

Boston Scientific signs definitive agreement to acquire CeloNova's interventional radiology business

New findings reveal association between colorectal cancer and melanoma drug treatment

Researchers find greater genetic diversity among cancer cells than anticipated

New method may extend use of noninvasive prenatal testing to detect chromosomal abnormalities

AACR rapid and dramatic responses in TRK fusion patients

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

No progression in joint damage in 84% of psoriatic arthritis patients

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

New tool could help identify patients most likely to benefit from chemoprevention

Specific gut bacteria can improve cancer immunotherapy, show studies

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

Researchers identify new regulatory pathway that may play vital role in basal-like breast cancer

Man dies after developing tapeworm tumors

Differences in vitamin D status may account for disparities in breast cancer survival rates

Accuray announces installation of CyberKnife M6 and TomoTherapy Systems at FALP Cancer Institute in Chile

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

Liquid biopsy provides physicians with up-to-date information about patient's cancer

Drugs that target malignant cells increase life expectancy in advanced breast cancer patients

CK5 protein marks ovarian cancer likely to be resistant to cisplatin

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News